Asked by: Charles Walker (Conservative - Broxbourne)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 2 March 2022 to Question 106670, on Diabetes and Eating Disorders, when the means of increasing awareness among healthcare professionals of the risks for those who have type 1 diabetes and an eating disorder will be finalised and rolled out across the NHS; and if he will make a statement.
Answered by Gillian Keegan - Secretary of State for Education
Following the initial pilot evaluation findings, NHS England and NHS Improvement are broadening the availability of services to support people with type 1 diabetes related disordered eating. Funding has been made available over two years for up to five additional pilot sites areas from 2022/23.
Future pilot site delivery will include raising awareness of the service and condition with healthcare professionals and the communities they serve. Various resources have been developed by the first two pilot sites, including risk assessment documents, protocol and learning materials. An updated version of the Management of Really Sick Patients with Anorexia Nervosa guidelines is due to be published shortly, including guidance for health professionals on managing patients with type 1 diabetes related disordered eating.
Asked by: Charles Walker (Conservative - Broxbourne)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what research his Department has undertaken on the potential link between covid-19 vaccine resistance and needle phobias; and whether his Department has made an assessment of the potential merits of (a) oral or (b) nasal ingestion of that vaccine to increase take-up; and if he will make a statement.
Answered by Maggie Throup
The Department commissions research through the National Institute for Health Research (NIHR). The NIHR is not currently supporting specific research on vaccine hesitancy and needle phobias. However, the NIHR and UK Research and Innovation have co-funded research on oral and nasal ingestion of the COVID-19 vaccine. Approximately £580,000 was awarded to Imperial College London for a study on two candidate vaccines administered to the respiratory tract. The NIHR is also providing infrastructure support to two phase one studies in this area through the University of Oxford and Imperial College London.